Tempest Therapeutics GAAP EPS of -$0.79 beats by $2.48
Source: SeekingAlpha
2025-11-05 13:00:58 ET
More on Tempest Therapeutics
- Tempest Therapeutics GAAP EPS of -$2.07 beats by $0.58
- Seeking Alpha’s Quant Rating on Tempest Therapeutics
- Historical earnings data for Tempest Therapeutics
- Financial information for Tempest Therapeutics
Read the full article on Seeking Alpha
For further details see:
Tempest Therapeutics GAAP EPS of -$0.79 beats by $2.48
Tempest Therapeutics Inc.
NASDAQ: TPST
TPST Trading
1.26% G/L:
$2.42 Last:
48,367 Volume:
$2.39 Open:
TPST Latest News
March 11, 2026 08:00:00 am
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
February 25, 2026 07:59:00 am
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
February 11, 2026 06:59:00 am
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
February 04, 2026 04:47:13 pm
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
TPST Stock Data
$11,923,730
4,617,735
0.1%
21
N/A
Biotechnology & Life Sciences
Healthcare
US
Brisbane
